18.03.2022 • NewsStolt-Nielsen

Stolthaven Studies Storage Terminal in Brazil

Dutch storage operator Stolthaven Terminals has signed a Memorandum of Understanding with the Pecém Industrial and Port Complex, a joint venture between the Ceará State Government and the Port of Rotterdam in the Netherlands, to study a new storage terminal in Pecém Port, Brazil.

The terminal will mainly provide storage and handling services for green hydrogen and associated products, and will also include a bonded storage facility for ammonia.

“Our teams from Pecém and Stolt are already working on technical studies that will allow us to advance on the viability of the project’s deployment in the Pecém port terminal area,” said Danilo Serpa, CEO of Pecém Industrial and Port Complex.

Stolthaven added that Pecém Port is connected to a wide gas distribution network and has huge potential for generating wind and solar power, both fundamental for producing green hydrogen.

The Rotterdam-based terminal group is also developing a new greenfield terminal in Turkey. The facility in Ceyhan, Adana, will provide storage and handling services to the Ceyhan Petrochemical Industrial Zone, which is being developed by Rönesans Holding.

Author: Elaine Burridge, Freelance Journalist

© Stolt-Nielsen
© Stolt-Nielsen

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.